HOME >> MEDICINE >> NEWS
Study Pinpoints Effectiveness Of Prostate Cancer Therapies To Patient Populations

Outcomes Measured In Relation To Radical Prostectomy, External Beam Radiation, And Seen Implant Therapy

Philadelphia, PA--Implanting radioactive-filled seeds into a cancerous prostate gland has been a largely sucessful method of treating the second-leading cancer killer among men for more than two decades. However, a new study says that, after an estimated 41-month follow-up, patients classified as high-risk had a poorer outcome after being treated with the seed implant therapy compared to those who underwent either radical prostectomy or external beam radiation. These findings are published in the September 16, 1998 issue of the Journal of the American Medical Association (JAMA). The study also concluded that no significant difference in outcome was noted in low risk patients across all treatment modalities for this short and limited follow-up period.

"These results suggest that a particular population of patients -- those we can pre-therapeutically determine to be "high risk" -- don't do as well with the seed therapy as judged by prostate specific antigen (PSA) levels, as with alternative forms of therapy," says Alan Wein, MD, senior investigator on the study and chief of urology at the University of Pennsylvania Cancer Center.

Penn researchers used collected data from 1,872 men who were treated for their localized prostate cancer between 1989 and 1997. The men underwent one of three treatment options: radical prostectomy, external beam radiation, or seed implant therapy offered at two clinical sites.

The researchers set out to measure the rate of disease-free survival for these patients. In doing so, they used three tests: PSA, biopsy Gleason score, and the American Joint Commission on Cancer staging (AJCC) T-stage.

As background, PSA blood tests measure the level of prstate-specific antigens in the blood: the results are reported as nanograms per milli
'"/>

Contact: Sue Montgomery
smontgom@mail.med.upenn.edu
(215) 349-5657
University of Pennsylvania School of Medicine
16-Sep-1998


Page: 1 2

Related medicine news :

1. Study of energy and health in Africa focuses spotlight on charcoal and forest management
2. Study shows promise in identifying kidney failure
3. Study shows patch therapy may be as effective as oral medications
4. Study shows soy is well accepted in school lunches
5. Study finds that coordinating care of chronically ill patients does not increase liability
6. Study provides new estimates of the causes of child mortality worldwide
7. Study finds factors linked to substance use disorder relapse among health care professionals
8. Study finds majority of women willing to accept cervical cancer vaccine for self and children
9. Study shows use of budesonide reduced the risk of asthma related events by 40% in children
10. Study shows risk of cardiac death after radiation for breast cancer has dramatically decreased
11. Study shows acrylamide in baked and fried food does not increase risk of breast cancer in women

Post Your Comments:
(Date:8/3/2015)... ... 03, 2015 , ... Sensato and Divurgent ... Healthcare Systems” This three-day, highly interactive and immersive workshop, has been developed ... to the tactics, techniques and practices required to design and develop highly secure ...
(Date:8/3/2015)... ... , ... A July 13 article from The Daily Mail titled "Jab ... That Can Last 'For Five Weeks'" discusses the use of stem cells to ... that harvesting stem cell-rich bone marrow from the hip, known as bone marrow stromal ...
(Date:8/3/2015)... San Ramon, CA (PRWEB) , ... August 03, ... ... a leading global insurance brokerage firm, announced today that Joe Williams has joined ... business development, sales, and delivering HUB's differentiated service model to his clients. Mr. ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... management and investigative services, has introduced a new logo and comprehensive brand ... that improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. ...
(Date:8/2/2015)... Provo, Utah (PRWEB) , ... August 03, 2015 ... ... and corporate training, will be attending and exhibiting at the Association for Healthcare ... August 7-8. , “We are pleased for the opportunity the AHDI conference ...
Breaking Medicine News(10 mins):Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 2Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 3Health News:Sensato and Divurgent are pleased to announce the development of it’s new program “Designing Secure Healthcare Systems” 4Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2Health News:Career Step to Exhibit at AHDI Conference in Alexandria, Virginia on August 7-8 2
(Date:8/3/2015)... FLORHAM PARK, N.J. , Aug. 3, 2015 /PRNewswire/ ... primary and secondary endpoints in a phase III study ... in adult patients with chronic non-cancer pain. Naldemedine is ... This is the third Phase III trial in which ... Study results showed that a 0.2 mg tablet ...
(Date:8/3/2015)... Israel , August 3, 2015 ... it received the statistical analysis of results from a study ... the BVX-005 phase II trial which took place in 2012, ... not exist at the time of the study- in particular ... the epidemic in the United States ...
(Date:8/3/2015)... Minn. , Aug. 3, 2015  EnteroMedics Inc. (NASDAQ: ... neuroblocking therapy to treat obesity, metabolic diseases and other ... has been appointed to the Board of Directors, ... a Class II Director until the 2018 annual meeting ... Ms. McDougal has served in an executive capacity ...
Breaking Medicine Technology:Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3Naldemedine Meets Primary Endpoint In Phase 3 Study For The Treatment Of Opioid-Induced Constipation 4Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 2Independent Results Show that BiondVax's Universal Flu Vaccine Administered in a Trial 3 Years ago Improves Immunogenicity Against Current Flu H3N2 Epidemic 3EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 2EnteroMedics Announces Appointment of Lori C. McDougal to the Board of Directors 3
Cached News: